FRANKFURT, Jan 29 (Reuters) - Roche's CEO said on Thursday that the Swiss drugmaker's expectations about opportunities in the future obesity drug market have not diminished since its Carmot Therapeutics takeover deal in late 2023.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.